Fabrizio Gasparini
Company: Novartis
Job title: Executive Director, Head Neurodegeneration-Neuroinflammation
Seminars:
Panel Discussion: Untangling the Future of Neuroimmunology Drug Development in the Wake of TREM2 Trial Results: To What Extent are Current TREM2 Models Fit For Purpose? 4:30 pm
Exploring how clinical validation of TREM2 will inform back translation and to what extent our current models still fit for purpose Navigating trial impact on preclinical model validation to better recapitulate neuroinflammatory pathology Evaluating the probable impact of inhibiting or stimulating microglia to reduce pathological neuroinflammation? How can we build on the next generation of…Read more
day: Conference Day One
TREM2 Modulation as Anti-Inflammatory Approach for the Treatment of AD – Is There a Space Beside Anti-Amyloid Beta & Tau Agents? 3:30 pm
Development of anti-amyloid antibodies were highly dependent on biomarker development and the correlation with therapeutic efficacy has been crucial The link with neuroinflammation, AD pathology and therapeutic efficacy is yet to be established Clinical assessment of agents acting at TREM2 and linking their mechanistic efficacy with the impact on AD pathology will be key to…Read more
day: Conference Day One